Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
11:27
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

ESMO 17th World Congress on Gastrointestinal Cancer 2015

 

1 - 4 July 2015 Barcelona
FAQs
   
Discussion forum - ESMO 17th World Congress on Gastrointestinal Cancer 2015
    Topic - Clinical Colon Cancer

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Recurrence-free survival according to treatment modality among elderly stage III colon cancer patients  Felice van Erning 1      7/6/2015 5:41:00 PM  
Grade III-IV toxicities among elderly stage III colon cancer patients receiving CAPOX or capecitabine  Felice van Erning 1      7/6/2015 5:39:00 PM  
Intensity of adjuvant chemotherapy regimens among elderly stage III colon cancer patients  Felice van Erning 1      7/6/2015 5:37:00 PM  
The first experience in Intraoperative Radiation Therapy for locally advanced or recurrent rectal cancer  Sergey Potemin 1      7/6/2015 7:55:00 AM  
Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC)  Isrid Sturm 1      7/2/2015 7:02:00 PM  
Pharmacokinetics of regorafenib in the phase 3 CONCUR and CORRECT trials in patients with metastatic colorectal cancer (mCRC)  Isrid Sturm 1      7/2/2015 6:48:00 PM  
Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup  Alfredo Falcone 1      7/2/2015 5:56:00 PM  
KRAS and BRAF gene subgroup analysis in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer  Howard Hochster 1      7/2/2015 5:53:00 PM  
The cost of survival gain in metastatic colorectal cancer (mCRC) in Spain  Teresa Sierra 1      7/2/2015 11:43:00 AM  
The cost of survival gain in metastatic colorectal cancer (mCRC) in France  Teresa Sierra 1      7/2/2015 11:38:00 AM  
A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)  Michel Ducreux 1      7/2/2015 11:32:00 AM  
An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)  faysal dane 1      7/2/2015 11:20:00 AM  
The Intestinal Stem Cell Marker SOX9 Predicts Relapse of Stage II Colon Cancer Patients  Maiken Lise Marcker Espersen 1      7/1/2015 1:39:00 PM  
Other RAS mutations incidence in CRCm in routine clinical practice: a center experience.  beatriz gonzalez astorga 1      6/30/2015 10:51:00 AM  
Aflibercept as a second line chemotherapy in metastatic colorectal cancer. One centre experience.  beatriz gonzalez astorga 1      6/30/2015 10:48:00 AM  
Circulating epidermal growth factor-like domain 7 of prognostic importance in patients with metastatic colorectal cancer  Torben Hansen 1      6/29/2015 10:30:00 PM  
Prognostic determinants in gastric cancer survival - the importance of metastatic lymph node ratio  Amanda Nogueira 1      6/23/2015 2:25:00 PM  
Regorafenib for metastatic colorectal cancer in community setting: a multicenter retrospective analysis in Hong Kong  Ka-On LAM 1      6/22/2015 5:08:00 PM  
Value of Pelvic Index for prediction of anastomotic leakage after laparoscopic low anterior resection in male rectal cancer  ATSUSHI TSURUTA 1      6/22/2015 5:01:00 PM  
Treatment of metastatic colorectal cancer. Experience of Centro Javeriano de Oncología - Hospital Universitario San Ignacio, Bogotá, Colombia  Annie Katherine Natera Melo 1      6/22/2015 4:43:00 PM  
A survey on current RAS-mutation testing practices in Europe  Annemarie Boleij 1      6/22/2015 1:44:00 PM  
K-RAS exon 2 mutations in advanced colorectal cancer: are they really so bad prognostic indicators? A mono-insititutional retrospective study  Vincenzo Dadduzio 1      6/22/2015 10:59:00 AM  
Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)  Vincenzo Ricci 1      6/18/2015 12:12:00 PM  
A multicentre, non-interventional, post-authorization study to observe in daily clinical practice the treatment duration of patients treated with bevacizumab in 1st line mCRC in Belgium.  Jean-Charles Goeminne 1      6/17/2015 11:08:00 PM  
Feasibility study of sequential adjuvant chemotheraphy with three months oxaliplatin-based regimen followed by three months capecitabine in patients with stage III and high risk stage II colorectal cancer: (JSWOG C2)  Hiroaki Tanioka 1      6/16/2015 3:01:00 AM  
Perioperative Oral Nutritional Support in Colorectal Cancer Patients May Improve Clinical and Health Economics Outcomes  Viktor Manasek 1      6/14/2015 10:25:00 AM  
CETUXIMAB AS THIRD LINE TREATMENT OF METASTATIC COLORECTAL CARCINOMA (mCRC) 5-YEAR EXPERIENCE FROM THE INSTITUTE OF ONCOLOGY AND RADIOLOGY OF SERBIA  Jelena Spasic 1      6/13/2015 12:16:00 PM  
Phase II Study of Tivantinib (ARQ 197) in Combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC)  Lorenza Rimassa 1      6/12/2015 7:11:00 PM  
Did the mRNA cutoff copy numbers in peripheral blood influence their relationship with prognosis in stage I-III colorectal cancer patients  Yong Liu 1      6/12/2015 12:45:00 PM  
Clinical Impact and Cost Implication of Routine MMR Protein Immunohistochemistry in High Risk Dukes B Colon Cancer  Kevin Chiu 1      6/6/2015 7:07:00 PM  
       




Most viewed poster for this congress
Poster: 98
Visits: 485
Title: LOCAL ADVANCED GASTRIC CANCER: OPTIMIZATION OF MANAGEMENT
Authors: Oleg Kshivets ,
Centre: surgery department, Kaluga Cancer Center

Poster most viewed in this topic
Poster: 14
Visits: 322
Title: First-line treatment with modified FOLFOX6 (mFOLFOX6) panitumumab or bevacizumab in patients with RAS/BRAF wild-type metastatic colorectal carcinoma
Authors: Fernando Rivera ,
Centre: Hospital Universitario Marqués de Valdecilla


 




PosterSessionOnline
Logo Draft
 
Logo Cert